Cornerstone Buys EKR Therapeutics To Expand Hospital Growth Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Cornerstone gains two commercial products for the acute-care hospital setting, Cardene and Retavase, with the acquisition of EKR Therapeutics for $125 million upfront and potential milestones.
You may also be interested in...
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.
Under Cornerstone’s Ownership, Zyflo Asthma Med Repositioned For Growth
After completing a reverse merger with Critical Therapeutics last year, Cornerstone has retooled the marketing message for the asthma medication and ramped up commercial support.
UroGen Approaches A Big Expansion In Bladder Cancer
The oncology company is preparing for the launch of UGN-102 for bladder cancer. CEO Liz Barrett talked to Scrip about the company’s next growth phase.